مباشر
PharmaVoiceCompetition is brewing between ADCs and bispecificsPromega BlogThe Hidden Switch That Controls Lysosome FunctionFierceBiotechCardiovascular-focused Kardigan plans to bring in cozy $320M haul from upcoming IPOFierceBiotechCaribou boosts case that off-the-shelf CAR-T matches autologous drugs ahead of phase 3CellDNA repair drives cisplatin-induced neuronal deathCellLong-term reversal of Duchenne muscular dystrophy via circular arRNA-guided exon skipping in monkeys and humansCellPersistent and transient senescent cells contribute to brain-barrier developmentCellContinuous modeling of primate embryogenesis from totipotency to early organogenesisCellRNA structure programs endogenous ADAR for precise and efficient editingFierceBiotech‘I’m a lot more optimistic today’: Mike Doustdar tells Fierce about pivotal first year as Novo Nordisk CEOFierceBiotechTakeda’s TYK2 inhibitor beats Bristol Myers’ Sotyktu in phase 3 psoriasis showdownEndpoints NewsTakeda's plaque psoriasis pill beats Bristol Myers' Sotyktu in Phase 3
BioWorld ٢٦ نوفمبر ٢٠٢٥

Chengdu Chipscreen Pharmaceutical describes new Mat2A inhibitors

Chengdu Chipscreen Pharmaceutical describes new Mat2A inhibitors

المصدر
المحتوى غير متاح. يرجى الرجوع إلى المصدر الأصلي.